Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Introduction: Cancer immunotherapy has revolutionized the treatment of patients with
advanced or metastatic non-small cell lung cancer (NSCLC). However, specific patient …

1. In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0-1, without
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …

Importance The combination of erlotinib and bevacizumab as initial treatment of epidermal
growth factor receptor (EGFR [OMIM131550])–mutant lung cancers improves progression …

Purpose Tumor growth relies on the sufficient blood supply and continuously requires new
blood vessels to maintain, which lead to vascular abnormalities (Folkman, N Engl J Med …

Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic drivers
in non-small-cell lung cancer (NSCLC). Significant developments have taken place which …

Non-small-cell lung cancer (NSCLC) constitutes 85% of patients diagnosed with lung
cancer. In metastatic cases, its treatment classically consists of systemic cytotoxic …

Introduction Previous studies suggested that epidermal growth factor receptor (EGFR)–
tyrosine kinase inhibitor (TKIs) plus bevacizumab could significantly prolong progression …

Abstract A substantial (40‑60%) proportion of patients with non‑small cell lung carcinoma
(NSCLC) have epidermal growth factor receptor (EGFR) mutations, a crucial therapeutic …

The treatment of advanced non–small-lung cancer (NSCLC) has steadily evolved over the
past 2 decades, and current therapy includes chemoimmunotherapy or targeted therapy with …